MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia Inc at the BMO Capital Markets Conference (Replay)
December 12, 2018 at 8:00 a.m. ET
Recent Press Releases
12/11/18MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11/12/18MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
NASDAQ GS | MYOK (Common Stock)
10/26/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.